Patents by Inventor Abraha Habtemariam

Abraha Habtemariam has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9598448
    Abstract: The present invention relates to the use of certain osmium containing complexes such as cytotoxic agents particularly for the treatment of cancer. There is also provided novel osmium containing complexes, as well as pharmaceutical formulations comprising such complexes.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: March 21, 2017
    Assignee: University of Warwick
    Inventors: Ying Fu, Peter John Sadler, Abraha Habtemariam
  • Publication number: 20160272663
    Abstract: The present invention relates to the use of certain osmium containing complexes such as cytotoxic agents particularly for the treatment of cancer. There is also provided novel osmium containing complexes, as well as pharmaceutical formulations comprising such complexes.
    Type: Application
    Filed: March 10, 2016
    Publication date: September 22, 2016
    Applicant: University of Warwick
    Inventors: Ying Fu, Peter John Sadler, Abraha Habtemariam
  • Patent number: 9408853
    Abstract: The present invention relates to novel iridium and/or rhodium containing complexes for use as a cytotoxic, such as an anti-cancer agent. There is also provided a method of preparing said compounds.
    Type: Grant
    Filed: May 20, 2011
    Date of Patent: August 9, 2016
    Assignee: University of Warwick
    Inventors: Abraha Habtemariam, Zhe Liu, Joan Josep Soldevila, Ana Maria Pizarro, Peter John Sadler
  • Patent number: 9296772
    Abstract: The present invention relates to the use of certain osmium containing complexes such as cytotoxic agents particularly for the treatment of cancer. There is also provided novel osmium containing complexes, as well as pharmaceutical formulations comprising such complexes.
    Type: Grant
    Filed: April 15, 2011
    Date of Patent: March 29, 2016
    Assignee: The University of Warwick
    Inventors: Ying Fu, Peter John Sadler, Abraha Habtemariam
  • Publication number: 20130065864
    Abstract: The present invention relates to novel iridium and/or rhodium containing complexes for use as a cytotoxic, such as an anti-cancer agent. There is also provided a method of preparing said compounds.
    Type: Application
    Filed: May 20, 2011
    Publication date: March 14, 2013
    Applicant: UNIVERSITY OF WARWICK
    Inventors: Abraha Habtemariam, Zhe Liu, Joan Josep Soldevila, Ana Maria Pizarro, Peter John Sadler
  • Publication number: 20130040925
    Abstract: The present invention relates to the use of certain osmium containing complexes such as cytotoxic agents particularly for the treatment of cancer. There is also provided novel osmium containing complexes, as well as pharmaceutical formulations comprising such complexes.
    Type: Application
    Filed: April 15, 2011
    Publication date: February 14, 2013
    Applicant: UNIVERSITY OF WARWICK
    Inventors: Ying Fu, Peter John Sadler, Abraha Habtemariam
  • Publication number: 20100291236
    Abstract: The present invention relates to osmium compounds of formula (I), their preparation and use in methods of treatment, particularly for cancer treatment.
    Type: Application
    Filed: August 10, 2007
    Publication date: November 18, 2010
    Applicant: THE UNIVERSITY OF WARWICK
    Inventors: Peter John Sadler, Anna Frances Acushla Peacock, Sabine Helena Van Rijt, Abraha Habtemariam
  • Publication number: 20090318402
    Abstract: A ruthenium (II) compound of formula (I) wherein X is halo or a neutral or negatively charged O, N- or S-donor ligand; Y is a counterion; m is 0 or 1; q is 1, 2 or 3; A is either: (i) (Ru)—NRN1RN2—RN3—(N), where RN1 and RN2 are independently selected from H, optionally substituted C1-7alkyl, C3-20 heterocyclyl and C5-20aryl, and RN3 is C1-2alkylene; or (ii) a nitrogen-containing C5-6aromatic ring, wherein the nitrogen ring atom is bound to the ruthenium atom, and the ring is also bound to the azo-nitrogen, either by a single bond wherein the bond is ? or ? to the nitrogen ring atom, or by a —CH2? group wherein the bond is x to the nitrogen ring atom; B is optionally substituted C1-7alkyl, C3-20heterocyclyl or C5-20aryl.
    Type: Application
    Filed: March 7, 2007
    Publication date: December 24, 2009
    Applicant: The University Court of the University of Edinburg
    Inventors: Sarah Dougan, Abraha Habtemariam, Michael Melchart, Peter John Sadler
  • Publication number: 20090186864
    Abstract: A ruthenium (II) compound of formula (I): or a solvate form thereof for use in a method of therapy, wherein: R1, R2, R3, R4, R5 and R6 are independently selected from H, C1-7 alkyl, C5-20 aryl, C3-20 heterocyclyl, halo, ester, amido, acyl, sulfo, sulfonamido, ether, thioether, azo and amino, or R1 and R2 together with the ring to which they are attached form a saturated or unsaturated carbocyclic or heterocyclic group containing up to three 3- to 8-membered carbocyclic or heterocyclic rings, wherein each carbocyclic or heterocyclic ring may be fused to one or more other carbocyclic or heterocyclic rings; X is halo or a neutral or negatively charged O, N— or S— donor ligand; Y is a counterion; m is ?1, 0, 1 or 2; q is 1, 2 or 3; RC1 and RC2 independently represent one or more optional substituents selected from hydroxy, C1-7 alkoxy, C5-20 aryloxy, C1-7 alkyl, carboxy, C1-7 alkyl ester and C5-20 aryl ester; RN1 and RN2 are independently selected from hydroxy, C1-7 alkoxy, C5-20 aryloxy, C1-7 alkyl, carbo
    Type: Application
    Filed: May 21, 2007
    Publication date: July 23, 2009
    Inventors: Abraha Habtemariam, Tijana Bugarcic, Peter John Sadler
  • Publication number: 20080096846
    Abstract: A ruthenium (II) compound of formula (I): or a solvate on prodrug thereof, wherein: R1, R1, R3, R4, R5 and R6 are independently selected from H, C1-7 alkyl, C5-20 aryl, C3-20 heterocyclyl, halo, ester, amido, acyl, sulfo, sulfonamido, ether, thioether, azo, amino, or R1 and R2 together with the ring to which they are attached form a saturated or unsaturated carbocyclic or heterocyclic group containing up to three 3- to 8-membered carbocyclic or heterocyclic rings, wherein each carbocyclic or heterocyclic ring may be fused to one or more other carbocyclic or heterocyclic rings; X is a neutral or negatively charged N- or S-donor ligand; Y is a counterion; in is 0 or 1; q is 1, 2 or 3; C? is C1-12 alkylene bound to two A groups; p is 0 or 1 and r is 1 when p is 0 and r is 2 when p is 1; and A and B are each independently O-donor, N-donor or S-donor ligands, and may be connected to one another. The compounds are used in cancer therapy.
    Type: Application
    Filed: August 19, 2005
    Publication date: April 24, 2008
    Inventors: Abraha Habtemariam, Peter Sadler
  • Patent number: 7241913
    Abstract: Ruthenium (II) compounds of formula (I) are useful in the treatment and/or prevention of cancer
    Type: Grant
    Filed: April 29, 2004
    Date of Patent: July 10, 2007
    Assignee: The University Court of the University of Edinburgh
    Inventors: Abraha Habtemariam, Peter John Sadler
  • Publication number: 20060258634
    Abstract: Ruthenium (II) compounds of formula (I) are useful in the treatment and/or prevention of cancer.
    Type: Application
    Filed: April 29, 2004
    Publication date: November 16, 2006
    Inventors: Abraha Habtemariam, Peter Sadler